Double metastatic cancer with lung and urothelial carcinoma responding to enfortumab vedotin: a case report and review of the literature

This exceptional case demonstrates a prolonged dual response of urothelial and lung adenocarcinomas to enfortumab vedotin. It highlights the potential role of nectin-4-targeted therapy beyond urothelial carcinoma and supports further investigation of this agent in non-small cell lung cancer.